Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer

Inclusion Criteria: * Informed consent form signed before performing any of the study's specific procedures. * ECOG performance status 0-2. * Age \> 18 and \< 75. * Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, greater than or equal to 1 cm (longest diameter) by spiral computed tomography (CT) scan and MRI or greater than or equal to 2 cm by other ordinary radiographic technique. * Histologically confirmed diagnosis of locally advanced esophageal. * Life expectancy of more than 3 months. * Use of an effective contraceptive method for patients of both sexes when there is a risk of conception and/or pregnancy. * No serious blood producing,abnormal function of heart,lung, liver, or kidney or immuno-deficiency * Neutrophils ≥3×109/L, platelet count≥100×109/L and haemoglobin≥9g/dL ,Creatinine ≤ 1.5 x NUL Exclusion Criteria: * Previous radiotherapy or chemotherapy * Pregnant or breast-feeding women * Drug abuse, unhealthy drug/alcohol addiction,or virus (HIV) infection * Evidence of distant metastasis * Participation in other clinical trials * Patients with aphthosis, complete obstruction, fistula or deep peptic ulcer in the esophagus, or haematemesis * Uncontrolled psychiatric disease or seizure * Patients not fit for the clinical trial judged by the investigators